{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:37:29Z","timestamp":1789983449081,"version":"4.0.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s13300-019-00728-6","type":"journal-article","created":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T21:02:37Z","timestamp":1575752557000},"page":"37-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes"],"prefix":"10.1007","volume":"11","author":[{"given":"Marc","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Dashora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,7]]},"reference":[{"issue":"3","key":"728_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ecl.2010.05.011","volume":"39","author":"DM Maahs","year":"2010","unstructured":"Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481\u201397. https:\/\/doi.org\/10.1016\/j.ecl.2010.05.011.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"15","key":"728_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa1610187","volume":"376","author":"EJ Mayer-Davis","year":"2017","unstructured":"Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002\u20132012. N Engl J Med. 2017;376(15):1419\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1610187.","journal-title":"N Engl J Med"},{"issue":"21","key":"728_CR3","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1056\/nejm199411243312107","volume":"331","author":"MA Atkinson","year":"1994","unstructured":"Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994;331(21):1428\u201336. https:\/\/doi.org\/10.1056\/nejm199411243312107.","journal-title":"N Engl J Med"},{"key":"728_CR4","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"A Katsarou","year":"2017","unstructured":"Katsarou A, Gudbjornsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016. https:\/\/doi.org\/10.1038\/nrdp.2017.16.","journal-title":"Nat Rev Dis Primers"},{"issue":"10138","key":"728_CR5","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/s0140-6736(18)31320-5","volume":"391","author":"LA DiMeglio","year":"2018","unstructured":"DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet (London, England). 2018;391(10138):2449\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(18)31320-5.","journal-title":"Lancet (London, England)"},{"issue":"14","key":"728_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/nejm199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386. https:\/\/doi.org\/10.1056\/nejm199309303291401.","journal-title":"N Engl J Med"},{"issue":"6","key":"728_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1056\/nejm200002103420603","volume":"342","author":"JM Lachin","year":"2000","unstructured":"Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381\u20139. https:\/\/doi.org\/10.1056\/nejm200002103420603.","journal-title":"N Engl J Med"},{"issue":"1","key":"728_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.2337\/db13-0782","volume":"63","author":"DM Nathan","year":"2014","unstructured":"Nathan DM, McGee P, Steffes MW, Lachin JM. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT\/EDIC study. Diabetes. 2014;63(1):282\u201390. https:\/\/doi.org\/10.2337\/db13-0782.","journal-title":"Diabetes"},{"issue":"Suppl","key":"728_CR9","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.2337\/dc15-S010","volume":"38","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. (7) Approaches to glycemic treatment. Diabetes Care. 2015;38(Suppl):S41\u20138. https:\/\/doi.org\/10.2337\/dc15-S010.","journal-title":"Diabetes Care"},{"issue":"11","key":"728_CR10","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1210\/jc.2016-2534","volume":"101","author":"AL Peters","year":"2016","unstructured":"Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3922\u201337. https:\/\/doi.org\/10.1210\/jc.2016-2534.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"728_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2337\/diab.46.2.271","volume":"46","author":"Diabetes Control and Complications Trial Research Group","year":"1997","unstructured":"Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes. 1997;46(2):271\u201386.","journal-title":"Diabetes"},{"issue":"7","key":"728_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2337\/diacare.11.7.567","volume":"11","author":"The DCCT Research Group","year":"1988","unstructured":"The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care. 1988;11(7):567\u201373. https:\/\/doi.org\/10.2337\/diacare.11.7.567.","journal-title":"Diabetes Care"},{"issue":"8","key":"728_CR13","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2337\/dc16-2723","volume":"40","author":"RA Gubitosi-Klug","year":"2017","unstructured":"Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM. Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT\/EDIC Study. Diabetes Care. 2017;40(8):1010\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"728_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-5448.2010.00754.x","volume":"12","author":"WV Tamborlane","year":"2011","unstructured":"Tamborlane WV. Severe hypoglycemia in youth with T1DM: going, going \u2026 but not yet gone. Pediatr Diabetes. 2011;12(1):1\u20133. https:\/\/doi.org\/10.1111\/j.1399-5448.2010.00754.x.","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"728_CR15","doi-asserted-by":"publisher","first-page":"R215","DOI":"10.1152\/ajpregu.00531.2011","volume":"302","author":"C Beall","year":"2012","unstructured":"Beall C, Ashford ML, McCrimmon RJ. The physiology and pathophysiology of the neural control of the counterregulatory response. Am J Phys Regul Integr Comp Phys. 2012;302(2):R215\u201323. https:\/\/doi.org\/10.1152\/ajpregu.00531.2011.","journal-title":"Am J Phys Regul Integr Comp Phys"},{"key":"728_CR16","unstructured":"NHS Digital. National Diabetes Audit 2017-18. Report 1: Care Processes and Treatment Targets. 2019. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/national-diabetes-audit\/report-1-care-processes-and-treatment-targets-2017-18-full-report. Accessed 24 July 2019."},{"issue":"8","key":"728_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/s2213-8587(17)30194-8","volume":"5","author":"JR Petrie","year":"2017","unstructured":"Petrie JR, Chaturvedi N, Ford I, Brouwers M, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597\u2013609. https:\/\/doi.org\/10.1016\/s2213-8587(17)30194-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"728_CR18","doi-asserted-by":"publisher","first-page":"e2983","DOI":"10.1002\/dmrr.2983","volume":"34","author":"H Meng","year":"2018","unstructured":"Meng H, Zhang A, Liang Y, Hao J, Zhang X, Lu J. Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Diabetes\/Metab Res Rev. 2018;34(4):e2983. https:\/\/doi.org\/10.1002\/dmrr.2983.","journal-title":"Diabetes\/Metab Res Rev"},{"issue":"6","key":"728_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/dom.12453","volume":"17","author":"JE Schopman","year":"2015","unstructured":"Schopman JE, Hoekstra JB, Frier BM, Ackermans MT, de Sonnaville JJ, Stades AM, et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. Diabetes Obes Metab. 2015;17(6):546\u201353. https:\/\/doi.org\/10.1111\/dom.12453.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"728_CR20","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1210\/jc.2012-2332","volume":"97","author":"J Farngren","year":"2012","unstructured":"Farngren J, Persson M, Schweizer A, Foley JE, Ahren B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(10):3799\u2013806. https:\/\/doi.org\/10.1210\/jc.2012-2332.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"728_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4158\/ep12100.Or","volume":"19","author":"SK Garg","year":"2013","unstructured":"Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013;19(1):19\u201328. https:\/\/doi.org\/10.4158\/ep12100.Or.","journal-title":"Endocr Pract"},{"key":"728_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diabres.2016.08.022","volume":"121","author":"H Guo","year":"2016","unstructured":"Guo H, Fang C, Huang Y, Pei Y, Chen L, Hu J. The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;121:184\u201391. https:\/\/doi.org\/10.1016\/j.diabres.2016.08.022.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"728_CR23","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702\u201310. https:\/\/doi.org\/10.2337\/dc16-0691.","journal-title":"Diabetes Care"},{"issue":"10","key":"728_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2337\/dc16-0690","volume":"39","author":"B Ahren","year":"2016","unstructured":"Ahren B, Hirsch IB, Pieber TR, Mathieu C, Gomez-Peralta F, Hansen TK, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016;39(10):1693\u2013701. https:\/\/doi.org\/10.2337\/dc16-0690.","journal-title":"Diabetes Care"},{"key":"728_CR25","doi-asserted-by":"publisher","DOI":"10.1530\/ec-18-0546","author":"L Liu","year":"2019","unstructured":"Liu L, Shao Z, Xia Y, Qin J, Xiao Y, Zhou Z, et al. Incretin-based therapies for patients with type 1 diabetes: a meta-analysis. Endocr Connect. 2019. https:\/\/doi.org\/10.1530\/ec-18-0546.","journal-title":"Endocr Connect"},{"issue":"2","key":"728_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/0897190014549837","volume":"29","author":"M DeGeeter","year":"2016","unstructured":"DeGeeter M, Williamson B. Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors. J Pharm Pract. 2016;29(2):144\u201359. https:\/\/doi.org\/10.1177\/0897190014549837.","journal-title":"J Pharm Pract"},{"issue":"2","key":"728_CR27","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.diabres.2013.01.020","volume":"100","author":"KV Hari Kumar","year":"2013","unstructured":"Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100(2):e55\u20138. https:\/\/doi.org\/10.1016\/j.diabres.2013.01.020.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"728_CR28","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1464-5491.2011.03331.x","volume":"28","author":"SL Ellis","year":"2011","unstructured":"Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabetic Med. 2011;28(10):1176\u201381. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03331.x.","journal-title":"Diabetic Med"},{"issue":"9","key":"728_CR29","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/s2213-8587(14)70115-9","volume":"2","author":"KJ Griffin","year":"2014","unstructured":"Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;2(9):710\u20138. https:\/\/doi.org\/10.1016\/s2213-8587(14)70115-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"728_CR30","doi-asserted-by":"publisher","first-page":"E876","DOI":"10.1210\/jc.2013-3633","volume":"99","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Yang L, Xiang Y, Liu L, Huang G, Long Z, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab. 2014;99(5):E876\u201380. https:\/\/doi.org\/10.1210\/jc.2013-3633.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"728_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495\u2013502. https:\/\/doi.org\/10.1038\/nrendo.2011.243.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"728_CR32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","volume":"60","author":"MJ Jurczak","year":"2011","unstructured":"Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890\u20138. https:\/\/doi.org\/10.2337\/db10-1328.","journal-title":"Diabetes"},{"key":"728_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255\u201370. https:\/\/doi.org\/10.1146\/annurev-med-051013-110046.","journal-title":"Annu Rev Med"},{"issue":"12","key":"728_CR34","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41(12):2560\u20139. https:\/\/doi.org\/10.2337\/dc18-1749.","journal-title":"Diabetes Care"},{"issue":"9","key":"728_CR35","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.2337\/dc18-0343","volume":"41","author":"JB Buse","year":"2018","unstructured":"Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018;41(9):1970\u201380. https:\/\/doi.org\/10.2337\/dc18-0343.","journal-title":"Diabetes Care"},{"issue":"9","key":"728_CR36","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2337\/dc18-0342","volume":"41","author":"T Danne","year":"2018","unstructured":"Danne T, Cariou B, Banks P, Brandle M, Brath H, Franek E, et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care. 2018;41(9):1981\u201390. https:\/\/doi.org\/10.2337\/dc18-0342.","journal-title":"Diabetes Care"},{"issue":"24","key":"728_CR37","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","volume":"377","author":"SK Garg","year":"2017","unstructured":"Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1708337.","journal-title":"N Engl J Med"},{"issue":"11","key":"728_CR38","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/s2213-8587(17)30308-x","volume":"5","author":"P Dandona","year":"2017","unstructured":"Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschope D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864\u201376. https:\/\/doi.org\/10.1016\/s2213-8587(17)30308-x.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"728_CR39","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.2337\/dc18-1087","volume":"41","author":"P Dandona","year":"2018","unstructured":"Dandona P, Mathieu C, Phillip M, Hansen L, Tschope D, Thoren F, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552\u20139. https:\/\/doi.org\/10.2337\/dc18-1087.","journal-title":"Diabetes Care"},{"issue":"9","key":"728_CR40","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc18-0623","volume":"41","author":"C Mathieu","year":"2018","unstructured":"Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41(9):1938\u201346. https:\/\/doi.org\/10.2337\/dc18-0623.","journal-title":"Diabetes Care"},{"issue":"6","key":"728_CR41","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2337\/dc18-1983","volume":"42","author":"C Mathieu","year":"2019","unstructured":"Mathieu C, Dandona P, Phillip M, Oron T, Lind M, Hansen L, et al. Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2. Diabetes Care. 2019;42(6):1081\u20137. https:\/\/doi.org\/10.2337\/dc18-1983.","journal-title":"Diabetes Care"},{"key":"728_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.15277\/\/bjd.2019.208","volume":"19","author":"U Dashora","year":"2019","unstructured":"Dashora U, Patel D, Gregory R, Winocour P, Dhatariya K, Nagi D. Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019). Br J Diabetes. 2019;19:66\u201372.","journal-title":"Br J Diabetes"},{"issue":"6","key":"728_CR43","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42(6):1147\u201354. https:\/\/doi.org\/10.2337\/dc18-2316.","journal-title":"Diabetes Care"},{"key":"728_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/acs.oprd.8b00017","volume":"22","author":"AR Aguill\u00f3n","year":"2018","unstructured":"Aguill\u00f3n AR, Mascarello A, Segretti ND, de Azevedo HFZ, Guimaraes CRW, Miranda LSM, et al. Synthetic strategies toward SGLT2 inhibitors. Org Process Res Dev. 2018;22:467\u201388.","journal-title":"Org Process Res Dev"},{"key":"728_CR45","unstructured":"European Pharmaceutical Review. EMA accepts marketing authorisation variation for Forxiga in adults with type-1 diabetes 2019. https:\/\/www.europeanpharmaceuticalreview.com\/news\/73381\/ema-forxiga-type-1-diabetes\/. Accessed 24 July 2019."},{"key":"728_CR46","unstructured":"National Institute for Health and Clinical Excellence. Technology appraisal guidance [TA597]: Dapagliflozin with insulin for treating type 1 diabetes 2019. https:\/\/www.nice.org.uk\/guidance\/TA597. Accessed 1 Sept 2019."},{"key":"728_CR47","unstructured":"Scottish Medicine Consortium. SMC2185: Dapagliflozin 5mg film coated tablets (Forxiga\u00ae) for treating Type 1 diabetes 2019. https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/dapagliflozin-forxiga-full-smc2185\/. Accessed 9 Sept 2019."},{"issue":"5","key":"728_CR48","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2337\/dc18-2149","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, et al. improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the intandem program. Diabetes Care. 2019;42(5):919\u201330. https:\/\/doi.org\/10.2337\/dc18-2149.","journal-title":"Diabetes Care"},{"key":"728_CR49","unstructured":"European Medicines Agency. Forxiga : EPAR - medicine overview 2019. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/forxiga-epar-medicine-overview_en.pdf. Accessed 1 Sept 2019."},{"key":"728_CR50","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019. https:\/\/doi.org\/10.2337\/dci19-0028.","journal-title":"Diabetes Care"},{"key":"728_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13820","author":"IC Lega","year":"2019","unstructured":"Lega IC, Bronskill SE, Campitelli MA, Guan J, Stall NM, Lam K, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019. https:\/\/doi.org\/10.1111\/dom.13820.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"728_CR52","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/m19-0085","volume":"170","author":"SJ Bersoff-Matcha","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764\u20139. https:\/\/doi.org\/10.7326\/m19-0085.","journal-title":"Ann Intern Med"},{"issue":"11","key":"728_CR53","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1089\/dia.2017.0267","volume":"19","author":"NS Patel","year":"2017","unstructured":"Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, et al. Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT2 inhibitor: an insulin pump suspension study. Diabetes Technol Therap. 2017;19(11):618\u201322. https:\/\/doi.org\/10.1089\/dia.2017.0267.","journal-title":"Diabetes Technol Therap"},{"issue":"4","key":"728_CR54","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1900\/rds.2016.13.217","volume":"13","author":"K Dhatariya","year":"2016","unstructured":"Dhatariya K. Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev Diabet Stud. 2016;13(4):217\u201325. https:\/\/doi.org\/10.1900\/rds.2016.13.217.","journal-title":"Rev Diabet Stud"},{"issue":"934","key":"728_CR55","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/pmj.79.934.454","volume":"79","author":"D Kamalakannan","year":"2003","unstructured":"Kamalakannan D, Baskar V, Barton DM, Abdu TA. Diabetic ketoacidosis in pregnancy. Postgrad Med J. 2003;79(934):454\u20137. https:\/\/doi.org\/10.1136\/pmj.79.934.454.","journal-title":"Postgrad Med J"},{"issue":"7","key":"728_CR56","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.2337\/dc17-0186","volume":"40","author":"FJR Morrison","year":"2017","unstructured":"Morrison FJR, Movassaghian M, Seely EW, Curran A, Shubina M, Morton-Eggleston E, et al. Fetal outcomes after diabetic ketoacidosis during pregnancy. Diabetes Care. 2017;40(7):e77\u20139. https:\/\/doi.org\/10.2337\/dc17-0186.","journal-title":"Diabetes Care"},{"issue":"10","key":"728_CR57","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/qjmed\/hcx124","volume":"110","author":"YK Wang","year":"2017","unstructured":"Wang YK, Li YH, Wu ST, Meng E. Fournier\u2019s gangrene. QJM. 2017;110(10):671\u20132. https:\/\/doi.org\/10.1093\/qjmed\/hcx124.","journal-title":"QJM"},{"issue":"9","key":"728_CR58","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1007\/s00268-005-0777-3","volume":"30","author":"H Yanar","year":"2006","unstructured":"Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, et al. Fournier\u2019s gangrene: risk factors and strategies for management. World J Surg. 2006;30(9):1750\u20134. https:\/\/doi.org\/10.1007\/s00268-005-0777-3.","journal-title":"World J Surg"},{"issue":"9","key":"728_CR59","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638\u201342. https:\/\/doi.org\/10.2337\/dc15-1380.","journal-title":"Diabetes Care"},{"key":"728_CR60","unstructured":"Trend UK. Type 1 diabetes: What to do when you are ill 2018. http:\/\/trend-uk.org\/wp-content\/uploads\/2018\/03\/A5_T1Illness_TREND_FINAL.pdf. Accessed 24 July 2019."},{"key":"728_CR61","unstructured":"Trend UK. For healthcare professionals: Appropriate use of SGLT2 inhibitors in type 2 diabetes: right person, right medication, right time 2018. https:\/\/www.mydiabetesmyway.scot.nhs.uk\/admin\/UploadedFiles\/Napp-HCP_SGLT2_TREND_FINAL.pdf. Accessed 24 July 2019."},{"issue":"10","key":"728_CR62","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1111\/dom.13811","volume":"21","author":"RM Goldenberg","year":"2019","unstructured":"Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes Obes Metab. 2019;21(10):2192\u2013202. https:\/\/doi.org\/10.1111\/dom.13811.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"728_CR63","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1089\/dia.2018.0246","volume":"20","author":"SK Garg","year":"2018","unstructured":"Garg SK, Peters AL, Buse JB, Danne T. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: A STICH protocol. Diabetes Technol Therap. 2018;20(9):571\u20135. https:\/\/doi.org\/10.1089\/dia.2018.0246.","journal-title":"Diabetes Technol Therap"},{"issue":"3","key":"728_CR64","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2337\/dc18-1444","volume":"42","author":"RW Beck","year":"2019","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400\u20135. https:\/\/doi.org\/10.2337\/dc18-1444.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"728_CR65","doi-asserted-by":"publisher","first-page":"S272","DOI":"10.2337\/dcS13-2030","volume":"36","author":"A Ceriello","year":"2013","unstructured":"Ceriello A, Kilpatrick ES. Glycemic variability: both sides of the story. Diabetes Care. 2013;36(Suppl 2):S272\u20135. https:\/\/doi.org\/10.2337\/dcS13-2030.","journal-title":"Diabetes Care"},{"issue":"1","key":"728_CR66","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2337\/dc14-1801","volume":"38","author":"S Ayano-Takahara","year":"2015","unstructured":"Ayano-Takahara S, Ikeda K, Fujimoto S, Hamasaki A, Harashima S, Toyoda K, et al. Glycemic variability is associated with quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2015;38(1):e1\u20132. https:\/\/doi.org\/10.2337\/dc14-1801.","journal-title":"Diabetes Care"},{"issue":"11","key":"728_CR67","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.2337\/dc18-1131","volume":"41","author":"J Lu","year":"2018","unstructured":"Lu J, Ma X, Zhou J, Zhang L, Mo Y, Ying L, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41(11):2370\u20136. https:\/\/doi.org\/10.2337\/dc18-1131.","journal-title":"Diabetes Care"},{"issue":"5","key":"728_CR68","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1464-5491.2011.03246.x","volume":"28","author":"MW Savage","year":"2011","unstructured":"Savage MW, Dhatariya KK, Kilvert A, Rayman G, Rees JA, Courtney CH, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med. 2011;28(5):508\u201315. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03246.x.","journal-title":"Diabet Med"}],"updated-by":[{"DOI":"10.1007\/s13300-019-00752-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000}}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-00728-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-019-00728-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-00728-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:09:34Z","timestamp":1724411374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-019-00728-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,7]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1007\/s13300-019-00728-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13300-019-00752-6","asserted-by":"object"}]},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,7]]},"assertion":[{"value":"24 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original article, Associated Medical Education Section has been published mistakenly. It has been removed from the original publication.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}